Pathology: breast cancer - adjuvant; la/mBC - HR positive; la/mBC - HR-positive - 1st line (L1); la/mBC - HR-positive - 2nd line (L2);
| breast cancer - adjuvant | la/mBC - HR positive | la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | ||||||||||||||
| MonarchE, 2021 | PALLAS, 2022 | PENELOPE-B, 2021 | KCSG-BR15-10, 2019 | MONARCH 3, 2017 | MonarchE, 2021 | PENELOPE-B, 2021 | PALOMA-1, 2016 | PALOMA-2, 2016 | MONALEESA-2, 2016 | MONARCH 2, 2020 | DAWNA-1, 2021 | FLIPPER, 2021 | PALOMA-3, 2016 | MONALEESA-7, 2018 | MONALEESA-3, 2018 | ||
| palbociclib plus endocrine therapy | 3 | T1 | T1 | T1 | |||||||||||||
| abemaciclib plus endocrine therapy | 2 | T1 | T1 | ||||||||||||||
| palbociclib plus fulvestrant | 2 | T1 | T1 | ||||||||||||||
| palbociclib plus letrozole | 2 | T1 | T1 | ||||||||||||||
| palbociclib | 1 | T1 | |||||||||||||||
| dalpiciclib plus fulvestrant | 1 | T1 | |||||||||||||||
| abemaciclib plus fulvestrant | 1 | T1 | |||||||||||||||
| ribociclib plus endocrine therapy | 1 | T1 | |||||||||||||||
| ribociclib plus fulvestrant | 1 | T1 | |||||||||||||||
| abemaciclib plus aromatase inhibitor | 1 | T1 | |||||||||||||||
| ribociclib plus letrozole | 1 | T1 | |||||||||||||||
| endocrine therapy | 0 | T0 | T0 | T0 | T0 | T0 | T0 | ||||||||||
| capecitabine | 0 | T0 | |||||||||||||||
| fulvestrant | 0 | T0 | T0 | T0 | T0 | T0 | |||||||||||
| aromatase inhibitor | 0 | T0 | |||||||||||||||
| letrozole | 0 | T0 | T0 | T0 | |||||||||||||